GeneDx Introduces ultraRapid Whole Genome Sequencing for NICU and PICU Patients, Offering Actionable Results in Just 48 Hours
GeneDx (Nasdaq: WGS), a leading provider of genomic insights to improve health outcomes, has announced its new ultraRapid Whole Genome Sequencing, aimed at delivering fast and comprehensive genomic insights for neonatal and pediatric patients in the Neonatal Intensive Care Unit (NICU) and Pediatric Intensive Care Unit (PICU). This groundbreaking development promises to provide actionable results in as little as 48 hours, significantly improving the speed and accuracy of diagnoses for critically ill infants and children.
Revolutionizing Diagnosis for Critically Ill Patients
In a statement about the launch, Dr. Paul Kruszka, Chief Medical Officer at GeneDx, expressed the company’s commitment to revolutionizing diagnostic processes. He stated, “Offering an ultraRapid genome is a testament to GeneDx’s commitment to shorten, and hopefully one day eliminate, the diagnostic odyssey for patients and their families.” This remark underscores the significance of GeneDx’s efforts to bring rapid genomic testing to the forefront of patient care.
The ultraRapid Whole Genome Sequencing is designed to provide faster, more accurate genetic diagnoses for infants and children in critical care settings, where every moment matters. Genetic diseases are one of the leading causes of infant mortality, and many of these conditions remain undiagnosed for extended periods. By offering a quicker diagnostic path, ultraRapid sequencing aims to help clinicians make informed decisions more swiftly, reducing unnecessary treatments and the length of hospital stays, while ultimately improving patient outcomes.
Studies show that for every baby who does not receive a timely genetic diagnosis, their NICU stay is extended by 15 to 20 days. These delays can contribute to increased healthcare costs and prolonged uncertainty for families. GeneDx’s ultraRapid sequencing seeks to address this issue by accelerating the process of identifying genetic conditions, thereby reducing NICU stays and enabling more targeted treatments. Moreover, genetic testing is associated with substantial healthcare savings. According to data, the potential for increased savings could amount to more than $15,000 per child, with a genetic diagnosis impacting the clinical management of over 60% of critically ill infants.
The Benefits of UltraRapid Genome Testing
UltraRapid genome testing presents numerous advantages for both patients and healthcare providers. The speed at which results are delivered makes it a game-changer in clinical decision-making. GeneDx’s ability to deliver actionable results within 48 hours means that clinicians can quickly tailor treatments, adjust care plans, and take the most effective course of action based on genetic findings. The expedited turnaround also allows for earlier interventions, which can have a profound impact on a patient’s prognosis.
Genetic diseases are often the root cause of serious health issues in newborns and children, but despite their prevalence, genetic testing remains underutilized in many critical care settings. It is estimated that up to 25% of patients in the NICU are likely to have an underlying genetic disorder, yet fewer than 5% of these patients undergo genetic testing. GeneDx’s ultraRapid Whole Genome Sequencing addresses this gap, making genetic testing more accessible and helping to identify conditions that may otherwise go undiagnosed.
Dr. Kruszka emphasized the importance of the testing in his statement: “Countless studies cite the benefits of an earlier diagnosis in children with genetic disease, and while we continue to invest in the ability to accelerate and improve access to testing, it is incumbent upon clinicians, health systems, policymakers, and payors, to recognize the benefits of this testing and offer it to more patients.”
Making UltraRapid Genome Sequencing Accessible
Starting in March, GeneDx’s ultraRapid genome test will be available for ordering through the GeneDx portal, as well as through the company’s integration with Epic Aura. This integration enables healthcare systems to easily offer this testing to more patients, ensuring that critical genomic insights are more readily available to those who need them most. With this convenient ordering process, GeneDx is working to expand the reach of its ultraRapid sequencing and ensure that more critically ill infants and children benefit from this innovative approach.
GeneDx’s ultraRapid sequencing builds upon the company’s long-standing expertise in genetic testing. With over 750,000 exomes and genomes sequenced, GeneDx has one of the largest and most diverse datasets available for analysis. This extensive experience allows GeneDx to continuously improve its lab processes and further enhance the efficiency of sequencing, analysis, and interpretation.
The company has also implemented automation and optimization in its laboratory workflow, resulting in faster processing times and lower costs for genetic testing. These innovations enable GeneDx to offer ultraRapid Whole Genome Sequencing at a fraction of the cost of traditional genomic testing, making it a more viable option for healthcare providers and patients alike. The company’s ability to accelerate testing while maintaining high standards of accuracy and quality is a testament to its technological advancements and commitment to improving patient care.
The Role of Genetic Diagnosis in Pediatric Care
Genetic testing plays a critical role in diagnosing and managing a wide range of pediatric conditions. Many genetic disorders are rare and may not present with obvious clinical symptoms, making them difficult to diagnose without advanced testing. By utilizing ultraRapid genome sequencing, healthcare providers gain access to a wealth of information that can help guide treatment decisions and improve patient outcomes.
The implications of an accurate genetic diagnosis are far-reaching. For example, genetic testing can help identify conditions that may require specialized treatment, inform decisions about potential clinical trials, and guide prognostic assessments. Additionally, an early genetic diagnosis can help families understand their child’s condition, provide emotional relief, and guide decision-making for future care.
GeneDx’s ultraRapid sequencing is expected to be particularly valuable in cases where every moment counts, such as in the NICU and PICU, where rapid decision-making is crucial. With the ability to deliver results in just 48 hours, the test offers a timely and actionable solution to address critical health concerns. This fast turnaround time allows healthcare providers to quickly implement the most appropriate care plan, potentially improving outcomes and quality of life for affected patients.
